Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies

Xia Cao; Junki Maruyama; Heyue Zhou; Yanwen Fu; Lisa Kerwin; Colin Powers; Rachel A. Sattler; John T. Manning; Alok Singh; Reyna Lim; Laura D. Healy; Sachi Johnson; Elizabeth Paz Cabral; Donghui Li; Lucy Lu; Arthur Ledesma; Daniel Lee; Susan Richards; Laura Rivero-Nava; Yan Li; Weiqun Shen; Karen Stegman; Benjamin Blair; Shinji Urata; Magumi Kishimoto-Urata; Jamie Ko; Na Du; Kyndal Morais; Kate Lawrence; Ianne Rivera; Chin I. Pai; Damien Bresson; Mark Brunswick; Yanliang Zhang; Henry Ji; Slobodan Paessler; Robert D. Allen

doi:10.1038/s41598-022-19780-7

Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies

Xia Cao, Junki Maruyama, Heyue Zhou, Yanwen Fu, Lisa Kerwin, Colin Powers, Rachel A. Sattler, John T. Manning, Alok Singh, Reyna Lim, Laura D. Healy, Sachi Johnson, Elizabeth Paz Cabral, Donghui Li, Lucy Lu, Arthur Ledesma, Daniel Lee, Susan Richards, Laura Rivero-Nava, Yan LiWeiqun Shen, Karen Stegman, Benjamin Blair, Shinji Urata, Magumi Kishimoto-Urata, Jamie Ko, Na Du, Kyndal Morais, Kate Lawrence, Ianne Rivera, Chin I. Pai, Damien Bresson, Mark Brunswick, Yanliang Zhang, Henry Ji, Slobodan Paessler, Robert D. Allen

Research output: Contribution to journal › Article › peer-review

Abstract

Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.

Original language	English (US)
Article number	15517
Journal	Scientific reports
Volume	12
Issue number	1
DOIs	https://doi.org/10.1038/s41598-022-19780-7
State	Published - Dec 2022

ASJC Scopus subject areas

General

Access to Document

10.1038/s41598-022-19780-7

Cite this

Cao, X., Maruyama, J., Zhou, H., Fu, Y., Kerwin, L., Powers, C., Sattler, R. A., Manning, J. T., Singh, A., Lim, R., Healy, L. D., Johnson, S., Paz Cabral, E., Li, D., Lu, L., Ledesma, A., Lee, D., Richards, S., Rivero-Nava, L., ... Allen, R. D. (2022). Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies. Scientific reports, 12(1), Article 15517. https://doi.org/10.1038/s41598-022-19780-7

Cao, X, Maruyama, J, Zhou, H, Fu, Y, Kerwin, L, Powers, C, Sattler, RA, Manning, JT, Singh, A, Lim, R, Healy, LD, Johnson, S, Paz Cabral, E, Li, D, Lu, L, Ledesma, A, Lee, D, Richards, S, Rivero-Nava, L, Li, Y, Shen, W, Stegman, K, Blair, B, Urata, S, Kishimoto-Urata, M, Ko, J, Du, N, Morais, K, Lawrence, K, Rivera, I, Pai, CI, Bresson, D, Brunswick, M, Zhang, Y, Ji, H, Paessler, S & Allen, RD 2022, 'Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies', Scientific reports, vol. 12, no. 1, 15517. https://doi.org/10.1038/s41598-022-19780-7

@article{9b224183c8e14ebfb287277c1564a37b,

title = "Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies",

abstract = "Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.",

author = "Xia Cao and Junki Maruyama and Heyue Zhou and Yanwen Fu and Lisa Kerwin and Colin Powers and Sattler, {Rachel A.} and Manning, {John T.} and Alok Singh and Reyna Lim and Healy, {Laura D.} and Sachi Johnson and {Paz Cabral}, Elizabeth and Donghui Li and Lucy Lu and Arthur Ledesma and Daniel Lee and Susan Richards and Laura Rivero-Nava and Yan Li and Weiqun Shen and Karen Stegman and Benjamin Blair and Shinji Urata and Magumi Kishimoto-Urata and Jamie Ko and Na Du and Kyndal Morais and Kate Lawrence and Ianne Rivera and Pai, {Chin I.} and Damien Bresson and Mark Brunswick and Yanliang Zhang and Henry Ji and Slobodan Paessler and Allen, {Robert D.}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1038/s41598-022-19780-7",

language = "English (US)",

volume = "12",

journal = "Scientific reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies

AU - Cao, Xia

AU - Maruyama, Junki

AU - Zhou, Heyue

AU - Fu, Yanwen

AU - Kerwin, Lisa

AU - Powers, Colin

AU - Sattler, Rachel A.

AU - Manning, John T.

AU - Singh, Alok

AU - Lim, Reyna

AU - Healy, Laura D.

AU - Johnson, Sachi

AU - Paz Cabral, Elizabeth

AU - Li, Donghui

AU - Lu, Lucy

AU - Ledesma, Arthur

AU - Lee, Daniel

AU - Richards, Susan

AU - Rivero-Nava, Laura

AU - Li, Yan

AU - Shen, Weiqun

AU - Stegman, Karen

AU - Blair, Benjamin

AU - Urata, Shinji

AU - Kishimoto-Urata, Magumi

AU - Ko, Jamie

AU - Du, Na

AU - Morais, Kyndal

AU - Lawrence, Kate

AU - Rivera, Ianne

AU - Pai, Chin I.

AU - Bresson, Damien

AU - Brunswick, Mark

AU - Zhang, Yanliang

AU - Ji, Henry

AU - Paessler, Slobodan

AU - Allen, Robert D.

PY - 2022/12

Y1 - 2022/12

N2 - Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.

AB - Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.

UR - http://www.scopus.com/inward/record.url?scp=85137929851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137929851&partnerID=8YFLogxK

U2 - 10.1038/s41598-022-19780-7

DO - 10.1038/s41598-022-19780-7

M3 - Article

C2 - 36109550

AN - SCOPUS:85137929851

SN - 2045-2322

VL - 12

JO - Scientific reports

JF - Scientific reports

IS - 1

M1 - 15517

ER -

Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this